Exchange: OTC·Updated 03:58 PM EST

BCLI Brainstorm Cell Therapeutics, Inc.

$0.95
$0.04
(4.04%)
Today
Reported EarningsNov 16
Mkt Cap$10.92M
Vol6,338.00

About BCLI

Brainstorm Cell Therapeutics, Inc. is a biotechnology company, which develops and commercializes autologous cellular therapies for the treatment of neurodegenerative diseases, including Amyotrophic Lateral Sclerosis, Progressive Multiple Sclerosis, Alzheimer's disease, and other neurodegenerative diseases. Its pipeline, NurOwn proprietary cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival, and improve neurological function. The company was founded by Irit Arbel on September 22, 2000 and is headquartered in New York, NY.
73

Bullish Sentiment

How do you feel about BCLI?

thres
$BCLI Even AI will tell you which ALS-Specific Drug (approved or not) has proven to be more popular with ALS patients. Most Campaigned-For Experimental Therapy: NurOwn Among unapproved clinical-stage treatments, NurOwn (an autologous stem-cell therapy developed by BCLI) has generated the most intense patient loyalty and grassroots mobilization. • Why Patients Rally Behind It. Many clinical trial participants and their families have shared dramatic personal testimonials claiming NurOwn stabilized their progression or restored lost function. Despite failing its initial Phase III primary endpoints and receiving a 17–1 vote against approval from an FDA advisory panel in 2023, thousands of patients petitioned regulators to keep it accessible. • Current Status. Following strong long-term survival data from its Expanded Access Program—where Brain Storm Cell Therapeutics reported that 9 out of 10 participants survived past five years—the therapy advanced toward a registrational Phase 3b trial.
9
ALSCellTherapy
$BCLI Seems like something is happening behind the scenes… “During the third quarter, we strengthened our leadership with the appointment of Professor Peter J. Pitts as Executive Chairman and broadened our engagement with regulators, potential commercial partners, and investors.”
4
DoctorJT
$BCLI Chaim, you may be the most absent, sickly communicative, and mistrustful CEO out there. Here are a sad few, of many, many examples: Q4 2019 EC, Chaim explicitly addressed the interim data from the hospital exemption program in Israel. He stated the company was looking at interim results and noted they may be able to publish in the spring of this year. Then, not a peep more about it. So, on the Q3 2020 EC, when asked a follow-up by an astute investor, whether efficacy data from the Israeli HEP would be presented or published, Chaim deferred to then-EVP and CDO, Dr Lindborg. Lindborg said BrainStorm would share the data ASAP, prioritizing regulatory agencies and ongoing trial investigators first, before wider public release. Yet, the data was never published or released. In a Feb 2026 press release, you state: ..”engages in high-level discussions regarding the pending Citizens Petition for Accelerated Approval…” yet, here we are Nov 2026 and not a peep more about it.
7
thres
$BCLI Fact: The Activist Movement: Driven by NurOwn led to approval of ACT for ALS: In 2020 and 2021, when BrainStorm’s first Phase 3 trial failed to meet its primary endpoints, patients who had experienced profound, life-altering improvements during the trial refused to let the therapy die. Led by No More Excuses! ALS Watch Dog Group, I AM ALS, and a fiercely dedicated network of grassroots advocates, patients flooded social media, petitioned Congress, and showed up at the FDA. Their message was clear: People dying of ALS do not have 10 to 15 years to wait for perfect data. They deserve the "Right to Try" promising therapies now. This massive pressure cooker directly resulted in the ACT for ALS, which was signed into law in December 2021 with nearly unanimous bipartisan support. It was a monumental victory completely manufactured by the patients themselves. To this day Nurown is not approved by FDA and still lacks funding for Phase 3B endurance trial to secure SPA approval.
6
ALSCellTherapy
$BCLI Compare to #NurOwn Survival Data - from trial baseline - vs recently approved pancreatic cancer drug Daraxonrasib: 🔹#NurOwn EAP • ~ 6.5 yr median • ~ 5x natural history (1.3 yrs) in PRO-ACT natural history (clinical trials) database of 17 #ALS trials 🔹Daraxonrasib trial • ~1.1 yr median • ~2x natural history (6.7 months) If SIX extra months of survival (2x) is enough to grant traditional approval of a cancer therapy, then FIVE extra years (5x) of survival should be enough to grant accelerated approval of NurOwn. Please respond to citizens' petition (FDA-2025-P-2109) and approve NurOwn
6
ALSCellTherapy
$BCLI That RWE showed unprecedented trach-free survival benefits as of October 2026. In the 10-person EAP: 🔹5 yr survival = 100% EAP vs <20% ALS natural history 🔹5 yr median survival benefit = 7.5 yrs EAP vs 2.5 yrs ALS natural history 🔹5/10 people still alive, trach-free 🔹EAP's 51 patient treatment years ≈ patient treatment years in short 28-wk P3 trial 🔹Median not yet reached by those in the treatment arm in the trial and EAP (N-N) where 4/6 are still alive (range 7.5 - 9.5 yrs) with 81% lower risk of trach or death
5
taryagg
$BCLI endless hype, no news that promised by CEO. Decades of his mismanagement. His word is mud.
4
thres
$BCLI This is so sad and it is all over FB. Coulda, woulda, shoulda … He was a prime candidate for Nurown Endurance Trial. All he had to do was snap his fingers and Nurown Phase 3b was a go. Next thing you know: "Eric Dane is a prominent national spokesperson and advocate for ALS (Amyotrophic Lateral Sclerosis) awareness following his diagnosis in April 2025. Before his tragic passing in February 2026 at the age of 53, the Grey's Anatomy and Euphoria star dedicated his final months to heavily lobbying for federal support and research." All he had to do was raise money for the clinical trial that mattered - Nurown Phase 3b. I can't understand why nobody (his media people) told him the Nurown Endurance Trial would have got going in minutes with him in it. Things could have been a lot different. He could still be eating sushi with his kids and perhaps he could have gone back to acting and living a long life.
4
Knuckles30
$BCLI watch for some price uptick after October 27 Th Nothing here is financial advice
4
uieriwer
$BCLI LOL this has been going on for years here. How does Chaim the scam man keep people invested.
3
whistleblower7
$BCLI NOW WE HAVE 90000 ON THE BID AT .99 SOMEONE SURE IS TEMPTING ME. WHAT HAPPENED TO THE EARNING REPORT?
1

Advertisement|Remove ads.